1. Home
  2. CYTH

CYTH

Cyclo Therapeutics Inc.

Logo Cyclo Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-24-2024 3:05pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

Founded: 1990 Country:
N/A
Employees: N/A City: GAINESVILLE
Market Cap: 33.3M IPO Year: N/A
Target Price: $3.30 AVG Volume (30 days): 110.2K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.23 EPS Growth: N/A
52 Week Low/High: $0.68 - $2.57 Next Earning Date: 01-01-0001
Revenue: $1,076,405 Revenue Growth: -21.76%
Revenue Growth (this year): 212.89% Revenue Growth (next year): 797.06%

Share on Social Networks: